3 Value Stocks Walking a Fine Line

Barchart·04/02/2026 03:10:17

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. That said, here are three value stocks climbing an uphill battle and some other investments you should look into instead.

Utz (UTZ)

Forward P/E Ratio: 10.3x

Tracing its roots back to 1921 when Bill and Salie Utz began making potato chips in their kitchen, Utz Brands (NYSE:UTZ) offers salty snacks such as potato chips, tortilla chips, pretzels, cheese snacks, and ready-to-eat popcorn, among others.

Why Should You Dump UTZ?

1. Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
2. Revenue base of $1.44 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
3. Underwhelming 0.2% return on capital reflects management’s difficulties in finding profitable growth opportunities

Utz is trading at $7.75 per share, or 10.3x forward P/E. Dive into our free research report to see why there are better opportunities than UTZ.

Bristol-Myers Squibb (BMY)

Forward P/E Ratio: 9.7x

With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.

Why Are We Cautious About BMY?

1. The company has faced growth challenges as its 2.6% annual revenue increases over the last five years fell short of other healthcare companies
2. Efficiency has decreased over the last five years as its adjusted operating margin fell by 10.3 percentage points
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

At $62.04 per share, Bristol-Myers Squibb trades at 9.7x forward P/E. Read our free research report to see why you should think twice about including BMY in your portfolio.

Artisan Partners (APAM)

Forward P/E Ratio: 8.8x

Founded in 1994 with a focus on autonomous investment teams and a "high-value-added" approach, Artisan Partners (NYSE:APAM) is an investment management firm that offers actively managed equity and fixed income strategies to institutional and individual investors.

Why Do We Think Twice About APAM?

1. Annual revenue growth of 5.9% over the last five years was below our standards for the financials sector
2. Incremental sales over the last five years were less profitable as its 3.4% annual earnings per share growth lagged its revenue gains

Artisan Partners’s stock price of $36.56 implies a valuation ratio of 8.8x forward P/E. Check out our free in-depth research report to learn more about why APAM doesn’t pass our bar.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.